Sorriso Pharmaceuticals
Sandy, US · Founded 2020 · 14 employees on LinkedIn · 2 known investors
Sorriso Pharmaceuticals develops orally administered antibody therapies, with a lead candidate (SOR102) in clinical trials for ulcerative colitis. The company focuses on treatments for gastrointestinal and inflammatory diseases.
Founders & leadership
CK
Ciara Kennedy, Ph.D.Executive
BD
Brian DorseyNamed on SEC filing
MG
Michael GreyNamed on SEC filing
MC
Mark ChinNamed on SEC filing
SD
Susan DubeNamed on SEC filing
Board
EM
Edward MathersBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$21.3M disclosed across 1 round · 2021
▶$21.3MraisedJan 2022 · 11 investors · BiotechnologyRule 506(b)
▶$21.3MraisedJan 2022 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Brian DorseyExecutive Officer
- Michael GreyDirector
- Edward MathersDirector
- Ciara Kennedy, Ph.D.Executive Officer, Director
- Mark ChinDirector
- Susan DubeExecutive Officer
- Offering amount
- $31.4M
- Amount sold
- $21.3M
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Sorriso Pharmaceuticals do?
- Sorriso Pharmaceuticals develops orally administered antibody therapies, with a lead candidate (SOR102) in clinical trials for ulcerative colitis. The company focuses on treatments for gastrointestinal and inflammatory diseases.
- Who are Sorriso Pharmaceuticals's investors?
- Sorriso Pharmaceuticals's investors include New Enterprise Associates (NEA), NEA Secondary.
- How much funding has Sorriso Pharmaceuticals raised?
- Sorriso Pharmaceuticals has disclosed $21.3M raised across 1 round.
- Where is Sorriso Pharmaceuticals headquartered?
- Sorriso Pharmaceuticals is headquartered in Sandy, US.